Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.27

-0.7%

Dec 15 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (9985)	1/15/2004 6:34:59 PM
From: A.J. Mullen	of 52153

JP Morgan- General Impressions It's always crowded. The difference is in the mood, and this year it was up. Lot's of interest in the 20% of companies that were unlisted. But, having attended a lot of these conferences, the mood seems to be a lagging indicator - if not a contrarian one. Genomics was interesting in that Celera, Incyte and Myriad didn't present, while HGSI did - without mentioning the word. On the otherhand, two private companies, working in the area, Perlegen and Genomic Health, attracted great interest. The speaker and CEO for Genomic Health was applauded before he spoke. I can't recall another time that has happened. Ashley

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next